Bristol-Myers Squibb Company
BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS
Last updated:
Abstract:
Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR.sub.4a or N; Y is CR.sub.4b or N; Z is CR.sub.4d or N; provided that zero or 1 of X, Y, and Z is N; and R.sub.1, R.sub.2, R.sub.3, R.sub.4a, R.sub.4b, R.sub.4c, and R.sub.4d are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
5 Aug 2020
Issue date:
8 Sep 2022